Considerable Proportion of Medical Device Adverse Events Reported Late
By Elana Gotkine HealthDay Reporter
THURSDAY, March 13, 2025 -- Although most manufacturer reports of medical device adverse events are reported on time, a considerable proportion are submitted late, according to a study published online March 12 in The BMJ.
Alexander O. Everhart, Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues conducted a cross-sectional study to describe the extent of late adverse event reporting by manufacturers to the U.S. Food and Drug Administration Manufacturer And User Facility Device Experience (MAUDE) database. Data were included from medical device manufacturers that submitted initial adverse event reports between Sept. 1, 2019, and Dec. 31, 2022.
The researchers identified 13,587 reports of deaths, 1,552,268 reports of injuries, and 2,866,693 reports of malfunctions received from 3,028 unique manufacturers and 88,448 unique medical devices during the study period. Overall, 71.0 percent of adverse events were reported within 30 days (on time), while 4.5 and 9.1 percent were reported between 31 and 180 days or after 180 days, respectively (both late). Missing or invalid data were provided by the manufacturer in 15.5 percent of reports. More than half (54.8 percent) of late reports were attributable to three manufacturers and 13 medical devices.
"MAUDE is an incomplete data source for understanding medical device safety issues, due partly to the timeliness of its reports," the authors write.
Several authors disclosed ties to the medical device and health care industries; one author disclosed being an expert witness.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-03-14 06:00
Read more

- FDA Approves Ctexli (chenodiol) for Cerebrotendinous Xanthomatosis
- Turning Off TV Better For Heart Health Of Folks Predisposed To Diabetes
- Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
- NSAIDs Linked To Lower Dementia Risk
- 'Telelactation' Support Boosts Breastfeeding Rates
- Remibrutinib Beneficial for Urticaria After H1-Antihistamine Treatment
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions